A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of JX09 in Healthy Adult Participants
Latest Information Update: 13 Dec 2024
At a glance
- Drugs JX-09 (Primary)
- Indications Resistant hypertension
- Focus Adverse reactions
- Sponsors Corxel Pharmaceuticals
Most Recent Events
- 27 Oct 2024 According to a CORXEL media release, Ji Xing Pharmaceuticals name changed to CORXEL.
- 22 Feb 2024 Status changed from not yet recruiting to recruiting.
- 01 Jan 2024 New trial record